Dynavax to Present at the Wedbush 2011 Life Sciences Conference

(firmenpresse) - BERKELEY, CA -- (Marketwire) -- 08/11/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it plans to present at the Wedbush 2011 Life Sciences Conference in New York on Wednesday, August 17, 2011 at 10:00 am EDT (1:00 pm PDT).

Brant Biehn, Chief Commercial Officer of Dynavax, and Shari Annes, Investor Relations of Dynavax, will provide a corporate overview presentation. To access the live webcast and the subsequent archived recording of the presentation, please log onto Dynavax's website at .



Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. The Company's lead product candidate is HEPLISAV™, a Phase 3 investigational adult hepatitis B vaccine designed to provide rapid and superior protection with fewer doses than current licensed vaccines. For more information visit .



Shari Annes
Investor Relations
510-665-7211

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: MARKET WIRE
Datum: 11.08.2011 - 13:00 Uhr
Sprache: Deutsch
News-ID 45169
Anzahl Zeichen: 0

contact information:
Town:

BERKELEY, CA

Kategorie:

Biotech

Diese Pressemitteilung wurde bisher 204 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Dynavax to Present at the Wedbush 2011 Life Sciences Conference"
steht unter der journalistisch-redaktionellen Verantwortung von

Dynavax Technologies (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Dynavax Presents Clinical Data From Lead Cancer Immunotherapy Candidate, SD-101, ...

BERKELEY, CA -- (Marketwired) -- 12/05/15 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced clinical data from an ongoing Phase 1/2 clinical trial evaluating intratumoral administration of SD-101 in the treatment of low-grade lympho ...

Dynavax Announces Presentation of Clinical Data at ASH Annual Meeting ...

BERKELEY, CA -- (Marketwired) -- 11/30/15 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will present clinical data at the 57th American Society of Hematology (ASH) Annual Meeting this weekend in Orlando, Florida. The det ...

Dynavax Reports Third Quarter 2015 Financial Results ...

BERKELEY, CA -- (Marketwired) -- 11/05/15 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the third quarter ended September 30, 2015.The Company had $220.7 million in cash, cash equivalents and marketable secu ...

Alle Meldungen von Dynavax Technologies